Adage Capital Partners Gp, L.L.C. Taysha Gene Therapies, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.43 - $3.25 $286,000 - $650,000	-200,000 Reduced 47.62%	220,000 $631,000
Q4 2023 Feb 14, 2024	SELL	$1.33 - $2.88 $1.44 Million - $3.11 Million	-1,080,000 Reduced 72.0%	420,000 $743,000
Q3 2023 Nov 14, 2023	BUY	$0.63 - $3.66 $945,000 - $5.49 Million	1,500,000 New	1,500,000 $4.74 Million

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $103M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.